PLPC™ PLATFORM
A structural platform.
A structural platform.
Multiple biological solutions.
The PLPC™ Platform integrates personalized immunobiology, advanced microneedle systems, nutraceutical solutions, and data intelligence verticals for diverse clinical, functional, and strategic needs.
From personalized protocols under the 1 Protocol · 1 Patient principle, to medical devices and corporate licensing models built upon a unified technological foundation.
What type of solution are you looking for?
Select the profile that best represents your current need to access the appropriate route and documentation.
I am a Patient / Family Member
I am looking for a personalized evaluation for cancer, autoimmunity, persistent inflammation, tissue damage, or functional recovery.
I am a Medical Professional
I seek to understand biological architectures, evaluation criteria, mechanisms, therapeutic integration, and clinical follow-up.
I seek Products / Technology
I want to learn about microneedle delivery systems, nutraceutical solutions, distribution, or biotechnological integration.
I represent an Organization
I am looking for information on intellectual assets, licensing, manufacturing, territorial expansion, alliances, or investment rounds.
CORE INFRASTRUCTURE
The platform that organizes the ecosystem
The PLPC™ Platform is the central technological asset that articulates biological architectures, formulations, personalized programs, delivery systems, development verticals, and longitudinal data intelligence.
PLPC™ Platform does not represent a single product. It is the overarching infrastructure from which multiple intellectual assets, products, and services are continuously developed.
Four strategic categories
ONCOVIX™
High-Complexity Personalized Immunobiology
Clinical-biological programs developed individually for each patient. 1 Protocol · 1 Patient. It includes multidisciplinary evaluation, clinical-molecular reading, architectural design, therapeutic integration, and longitudinal follow-up.
APHELAR™
Microneedle Systems / Medical Device
Advanced family of microneedle systems designed for localized, reproducible, and traceable delivery of formulations strictly compatible with PLPC™ Platform verticals.
Variants: APHELAR™-IO, APHELAR™-TOL, and APHELAR™-REG.
ABIMPROSYC™
Specialized Nutraceutical Solutions
- T-Defense: Antitumoral immune support.
- Sport: High performance and rapid recovery.
- Vitalis: Longevity and healthy aging.
- Regenera: Support for degenerative processes.
Investors & Partners
Assets, Licensing and Global Expansion
Corporate and strategic route for organizations interested in capital investment, licensing, manufacturing, distribution, territorial alliances, and full access to the Investor Data Room.
TECHNOLOGY & DATA
The engines powering the ecosystem
PLPC-DB™
Immunobiological Development Vertical
Vertical strictly oriented towards the development of programmable and pharmacologizable immunobiological assets. It features candidate selection, tumor-line selectivity orientation, mechanism characterization, and translational clinical development.
VISIT PLPC-DB™ ↗STIP™
Data Intelligence Protocol
Intelligence protocol completely aligned with New Approach Methodology (NAM), aimed at integrating clinical profiling, biomarkers, longitudinal evidence, and advanced analysis to produce relevant human data for medical decision-making utility.
EXPLORE STIP™ BIOAI
SCIENTIFIC FOUNDATION
Structural science and global collaboration
The PLPC™ Platform integrates verified scientific evidence, multidisciplinary medical expertise, biotechnological structural development, secure traceability, and a robust international network designed to transform science into impactful human solutions.
- Publications & Evidence: Peer-reviewed articles, international congresses, and rigorous scientific validation.
- Multidisciplinary Team: Experts in clinical oncology, immunology, and technological profiling.
- Technological Development: Scalable assets and intelligent medical integration.
- OGRD Alliance: Global international network for institutional collaboration and sustained expansion.
Frequently Asked Questions
Is the PLPC™ Platform a specific medical treatment?
No. The PLPC™ Platform is the overarching technological ecosystem from which different clinical programs, physical products, medical devices, and intelligence/development verticals are independently created.
Are ONCOVIX™ and APHELAR™ the same product?
No. ONCOVIX™ is a high-complexity personalized immunobiological clinical program. APHELAR™ is a distinct family of physical microneedle systems (classified as a medical device) used for localized delivery.
Is ABIMPROSYC™ part of the ONCOVIX™ clinical program?
ABIMPROSYC™ is proudly part of the PLPC™ Platform ecosystem, but it operates as a completely distinct and independent nutraceutical formulation family available to a wider audience.
What exactly are PLPC-DB™ and STIP™?
PLPC-DB™ is our proprietary immunobiological development and engineering vertical. STIP™ (Data Intelligence Protocol) is our advanced software/data framework for clinical profiling, managing biomarkers, and capturing longitudinal evidence.
How do I know which ecosystem route is right for my specific case?
You can select your specific profile at the top of this page or request direct guidance within the ONCOVIX™ section to be immediately directed to the appropriate landing page, forms, and assessment process.
One Ecosystem. Multiple Solutions.
Find the right strategic path within the PLPC™ Platform to access personalized clinical protocols, advanced medical devices, or corporate investment alliances.
Institutional Notice: The information presented on this core site is strictly institutional, informative, and orientational in nature. The qualification for protocols and clinical programs does not constitute a guarantee of medical remission, clinical response, or any predetermined physiological outcome. By utilizing our clinical and corporate orientation forms, you acknowledge and fully accept our Privacy and Data Processing Policy.